TY - JOUR
T1 - Dual-Time-Point F-18 FDG PET/CT for Evaluation of Intrathoracic Lymph Nodes in Patients with Non-Small Cell Lung Cancer
AU - Shinya, Takayoshi
AU - Rai, Kammei
AU - Okumura, Yoshihiro
AU - Fujiwara, Keiichi
AU - Matsuo, Kiyoshi
AU - Yonei, Toshiro
AU - Sato, Toshio
AU - Watanabe, Kazuhiko
AU - Kawai, Haruyuki
AU - Sato, Shuhei
AU - Kanazawa, Susumu
PY - 2009/4
Y1 - 2009/4
N2 - PURPOSE:: The aim of this study was to evaluate the diagnostic capacity of F-18 fluorodeoxyglucose dual-time-point (DTP) positron emission tomography (PET)/computed tomography (CT) for intrathoracic lymph node (LN) metastases in patients with nonsmall cell lung cancer (NSCLC). MATERIALS AND METHODS:: Thirty-four patients had DTP PET/CT, with 60 minutes and 2-hour scans (n = 19, NSCLC; n = 15, benign pulmonary disease). LN diagnoses were confirmed by surgery or clinical follow-up (n = 14, metastatic LNs; n = 45, nonmetastatic LNs; n = 39, inflammatory LNs). RESULTS:: The maximum standardized uptake value (SUVmax) in the metastatic group was significantly higher than those in the nonmetastatic and inflammatory groups on both early- and delayed-phase imaging (each P < 0.0001). The retention index (RI) of SUVmax (RI-SUVmax) in the metastatic group was significantly higher than in the nonmetastatic (P = 0.0008) and inflammatory groups (P = 0.0074). No significant difference was found between SUVmax values of the nonmetastatic and inflammatory groups on early- (P = 0.6461) or delayed-phase (P = 0.6913), or between RI-SUVmax values of the nonmetastatic and inflammatory groups (P = 0.5717). For early-phase SUVmax, the cut-off value for highest accuracy with metastatic LNs was 3.61, yielding a sensitivity of 86.67% and a specificity of 88.00%. For delayed-phase SUVmax, the cut-off value was 4.00, yielding a sensitivity of 91.6% and specificity of 92.9%. For RI-SUVmax, the cut-off value was 20.91%, yielding a sensitivity of 73.6% and specificity of 75.9%. CONCLUSIONS:: DTP PET/CT with a semiquantitative technique may improve diagnostic capacity for nodal staging of NSCLC.
AB - PURPOSE:: The aim of this study was to evaluate the diagnostic capacity of F-18 fluorodeoxyglucose dual-time-point (DTP) positron emission tomography (PET)/computed tomography (CT) for intrathoracic lymph node (LN) metastases in patients with nonsmall cell lung cancer (NSCLC). MATERIALS AND METHODS:: Thirty-four patients had DTP PET/CT, with 60 minutes and 2-hour scans (n = 19, NSCLC; n = 15, benign pulmonary disease). LN diagnoses were confirmed by surgery or clinical follow-up (n = 14, metastatic LNs; n = 45, nonmetastatic LNs; n = 39, inflammatory LNs). RESULTS:: The maximum standardized uptake value (SUVmax) in the metastatic group was significantly higher than those in the nonmetastatic and inflammatory groups on both early- and delayed-phase imaging (each P < 0.0001). The retention index (RI) of SUVmax (RI-SUVmax) in the metastatic group was significantly higher than in the nonmetastatic (P = 0.0008) and inflammatory groups (P = 0.0074). No significant difference was found between SUVmax values of the nonmetastatic and inflammatory groups on early- (P = 0.6461) or delayed-phase (P = 0.6913), or between RI-SUVmax values of the nonmetastatic and inflammatory groups (P = 0.5717). For early-phase SUVmax, the cut-off value for highest accuracy with metastatic LNs was 3.61, yielding a sensitivity of 86.67% and a specificity of 88.00%. For delayed-phase SUVmax, the cut-off value was 4.00, yielding a sensitivity of 91.6% and specificity of 92.9%. For RI-SUVmax, the cut-off value was 20.91%, yielding a sensitivity of 73.6% and specificity of 75.9%. CONCLUSIONS:: DTP PET/CT with a semiquantitative technique may improve diagnostic capacity for nodal staging of NSCLC.
KW - Dual-time-point
KW - F-18 FDG
KW - Intrathoracic lymph node
KW - Non-small cell lung cancer (NSCLC)
KW - PET/CT
UR - http://www.scopus.com/inward/record.url?scp=67650637712&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=67650637712&partnerID=8YFLogxK
U2 - 10.1097/RLU.0b013e31819a1f3d
DO - 10.1097/RLU.0b013e31819a1f3d
M3 - Article
C2 - 19300050
AN - SCOPUS:67650637712
SN - 0363-9762
VL - 34
SP - 216
EP - 221
JO - Clinical Nuclear Medicine
JF - Clinical Nuclear Medicine
IS - 4
ER -